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Background: (Buccalin ®) is a Bacterial Lysates (BL) that belongs to a family of immune-stimulators, developed more
than 30 years ago and it still has a role in the prophylaxis of Recurrent Respiratory Tract Infections (RRTI). However,
original studies were conducted with an approach that does not seem to be aligned with the present methodologies.
In addition, concomitant therapies substantially improved in the last decades. These two reasons strongly suggested to
update our knowledge on the capacity of this bacterial lysate (Buccalin ®) to reduce the number of days with infectious
episodes in patients with RRTI.
Methods: A double blind, placebo-controlled, randomized, multicentre study was programmed (EudraCT
code: 2011-005187-25). The reduction of the number of days with infectious episodes (IE) was the primary
endpoint. Secondary endpoints were the number of IE, the use of concomitant drugs, the efficacy on signs and
symptoms of RRTI and the safety of the drug. Patients were treated according to the registered schedule and were
followed up for a period of 6 months.
Results: From a cohort of 188 patients eligible for the study, 90 were included in the active group and 88 in the
placebo group. The study was completed in 170 patients. A significant reduction of the number of days with IE was
observed (6.57 days in the active group and 7.47 in the placebo group). Secondary endpoints were only partially
achieved. No virtual adverse events related to the treatment were recorded.
Conclusion: The administration of bacterial lysate (Buccalin ®) in patients with RRTI had the capacity to significantly
reduce the number of days with IE in a multicentre, randomized, placebo controlled, clinical study. The treatment
was safe. Of note, all patients were free to be treated with the best concomitant therapies. In these conditions, the
positive results observed demonstrated that this bacterial lysate has maintained its capacity of reducing the days
with infections in patients with RRTI, also in association to the concomitant therapies available nowadays.
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Recurrent infections of the respiratory tract are frequent
not only in children [1], but also in adults [2]. Otitis,
rhinitis, sinusitis, pharyngo-tonsillitis, laryngitis, bron-
chitis and lower airways infections are the most frequent
events. In addition, these disease conditions are fre-
quently associated to allergy symptoms, such as rhinitis
and asthma. The large use of locoregional and systemic
steroid, NSAID and antibiotics, significantly reduces the
duration of these diseases, but, at present, few drugs
have an impact on the frequency of recurrences as well
as the number of days of disease during the cold season
[2-5]. Many decades ago, the bacterial lysates were intro-
duced in human therapy in order to control recurrent
infections [6]. Notably, it has been shown that patients
affected with these diseases are virtually unable to have a
naturally induced immune-response at mucosal level [7].
For this reason, different approaches were described to
obtain a bacterial lysate suitable to induce an efficient
immune-response in treated patients. Thus, the lysis was
performed using a chemical approach, such as alkaline
lysis, or using physical methods such as heat or mechan-
ical fragmentation. Also the administration route was
different, including sublingual administration and gas-
troenteral absorption. The treatment schedules were dif-
ferent, from few days of treatment per month to a daily
administration for months. Finally, also posology was
heterogeneous, ranging from a very large number of
bacterial bodies-equivalents [8] to lyophilised soluble
bacterial proteins [5]. While originally, the clinical ef-
fects of these drugs were described and an activation of
non specific locoregional immune-response was observed
in treated patients [9], the fine mechanism of action of
these drugs was clarified only recently. At present, it has
been shown that bacteria lysates have the capacity of indu-
cing the maturation of dendritic cells [10,11] and, following
this maturation, a functionally efficient immune-response
is expected. Indeed, this initial stimulation of the innate
immune system is followed by the recruitment of a func-
tionally efficient recruitment of T and B lymphocytes
resulting [12-14] in the secretion of specific IgA directed to
administered bacterial antigens in the mucosal fluids, such
as saliva [8]. This cooperation between innate and adaptive
immune-response was considered responsible for the clin-
ical efficacy of the approach [8,15].
Of note, these mechanisms were clearly defined for
that group of drugs (which included both chemical and
mechanical lysates) that are administered in the oral mu-
cosa. Other drugs, such as Buccalin ®, are characterized
by a different route of administration. Indeed, Buccalin
is constituted by four different microbes (Streptococcus
pneumoniae, Streptococcus agalactiae, Staphylococcus
aureus and Hemophilus influenzae) that are killed using
heat, then administered as gastro-resistant tablets. Studiesthat have been carried out on the mechanism of action of
bacterial lysate (Buccalin ®) in patients with recurrent re-
spiratory infections demonstrated clinical efficacy of the
drug [16-18]. Other studies demonstrated also an increase
in the concentration of secretory IgA, suggesting that the
administration of this bacterial lysate, either by using the
adaptive arm, or by using the innate arm of the immune-
response, is efficient in potentiating the locoregional
immune-response [19-21]. To this experimental evidence,
it should be added that in previous years, the drug has
been extensively used to successfully prevent respiratory
tract infections. However, it is a common notion that
clinical trials, during 80s and 90s, were conducted in a
clinical and epidemiological environment different from
the present. In particular, the frequency of resistant bac-
teria, in community acquired respiratory tract infections,
was more rare than today and the therapeutic armament-
arium available was also different and less powerful. In this
context, it should also be noted that the clinical trial rules
of those periods were different from the extremely accur-
ate rules of the present.
For all these reasons, a double blind, placebo controlled,
multicentre clinical study was conducted to evaluate, using
updated and rigorous clinical trial technique, the effect of
bacterial lysate (Buccalin ®) on the number of days with IE
in patients suffering from RRTI. In this paper, we describe
the clinical trial and demonstrate that the treatment with
this bacterial lysate is suitable to significantly reduce the
number of days with infectious episodes.
Methods
Study design
This was a double blind, randomized vs placebo, multi-
centre clinical study on the efficacy and tolerability of,
a bacterial lysate with immune-stimulating properties
(Buccalin ®), in the prophylaxis of the infectious episodes
of upper and lower airways. Primary endpoint of the
study was the reduction of the number of days with in-
fectious episodes in a follow up period of 6 months,
starting from the beginning of the treatment, in the
group of treated patients, compared with the placebo
group. Secondary endpoints were the reduction of a) the
number of infectious episodes; b) the frequency and se-
verity of both higher and lower respiratory tract infec-
tions, evaluated at 4 and 6 months from the beginning
of the treatment; c) the efficacy on different signs and
symptoms related to IE. In addition, other secondary
endpoints were the disease free period after the end of
the treatment, the days of work/school lost and the glo-
bal efficacy and tolerability, evaluated by the investiga-
tors and the well being, evaluated by the patients using a
five-point scale. Finally, the occurrence of adverse reac-
tions was also recorded. The study was first approved by
the Ethical Committee of the Centre of the Principal
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ticipants in the study. This study was conducted according
to the Good Clinical Practices (GCP) procedures.
Patient selection
Patients (age 18 – 65) were considered eligible if, during
the previous year, a) had suffered from two to six infec-
tious episodes of the respiratory tract, b) were negative
for any pathological condition interfering with the present
study and c) were able to understand and manage the
study protocol. Exclusion criteria were a) the presence
of acute (either infectious or non infectious) episodes,
requiring hospitalization or intensive therapy at the mo-
ment of the randomization; b) gastro-oesophageal reflux;
c) auto-immune diseases; d) treatment with immunoglobu-
lins, immune-stimulants, cytokines, interferons, systemic
steroids and anti-neoplastic drugs in the two weeks preced-
ing the study; e) known allergy to the study drug; f) preg-
nancy or breastfeeding; g) other concomitant clinical
trial(s); h) incapacity of understanding the protocol because
of language or any other reasons.
Study population
The study was carried out in 10 different centres. Each
centre had the objective to recruit 18 patients. Indeed,
a total of 180 patients were expected to be enrolled in
the study. Ninety were randomized in the active group,
whereas 90 in the placebo group. A drop out on 20%
was foreseen: for this reason, 140 patients (70 active and
70 placebo) were expected to complete the study and to
be evaluable. Indeed, a sample size of 70 in each group
was expected to have a 90% power to detect a difference
in mean of 10 (Buccalin vs placebo), assuming a com-
mon standard deviation of 18, using a two-group t-test
with a 0.05 two-sided significance level.
Randomization protocol
The randomized list was based on the RANUNI random
number generator of the SAS software (SAS Institute,
Cary, NC, USA). The allocation ratio was 1:1 to treatments
bacterial lysate and placebo, with a block size of 4.
Treatment
The study period was six months and was divided in 4
treatment cycles. Every cycle lasted 30 days: the first
3 days, the treatment (bacterial lysate (Buccalin ®) SIT,
gastro-resistant tablets) was administered according to
the registration dossier: one tablet on day 1, two tab-
lets on day 2 and four tablets on day 3, while fasting.
Buccalin ® is constituted by a mixture of Streptococcus
pneumoniae (1 × 109 inactivated bacterial bodies), Strepto-
coccus haemolyticus (1 × 109 inactivated bacterial bodies),
Staphylococcus aureus (1 × 109 inactivated bacterial bodies)
and Hemophilus influenzae (1.5 × 109 inactivated bacterialbodies). The placebo group received the same schedule but
the drug consisted of gastro-resistant tablets containing
only excipients (lactose, micro-crystalline cellulose). In the
following 28 days patients did not receive any other
immune-stimulation. Both the drug and the placebo re-
spectively were produced by SIT srl (AIFA authorization
number aM- 229/2009 of December, 11th, 2009) and
IBNSavio srl (AIFA authorization number aAmm-49/
2011 of May, 6th, 2011); packaging trials were made by
Mipharm srl (AIFA authorization number aM-77/2011 of
May 27th, 2011) according to the randomization list.
Upon request of the investigators, the boxes were sent to
the different centres in blocks of 4 blisters. An adhesive
part of the label was also stuck to the CRF. Thus, the
Clinical Investigators used the unique ID number to
identify enrolled patients in the study. Patients, investiga-
tors and the biostatistician involved in the study analysis
worked in blind conditions. Only after the closure of the
database the randomization list was opened.
Visits
Five visits were scheduled. The first visit started with the
evaluation of patients’ eligibility. In eligible patients, the
informed consent was obtained, the patient’s history was
collected with specific reference to the number and type
of infectious episodes and to the treatments adopted.
Then, the patient was instructed on the nature of a
placebo-controlled study, on treatment schedule and on
the compilation of the personal diary. Finally, the patient
was randomized, the drug was given and the protocol
started. The second visit was scheduled after the end of
the fourth week. In this visit, the occurrence of adverse
reactions, any day of hospitalization, any day of absence
from work and school, the assumption of concomi-
tant therapies (such as NSAIDs, antibiotics, local or
systemic corticosteroids, anti cough drugs, mucolytics,
expectorants) and any other relevant physiologic or patho-
logic events were recorded. Then the first month patient’s
diary was retired and the compliance to the treatment was
verified by retiring the unused study drug. The drug for
the following month was given to the patient at the end
of the visit. The third and the fourth visit, scheduled
after 8 and 12 weeks from the beginning of the treat-
ment, were largely superimposable to the second visit.
The fifth and final visit verified all the above-mentioned
points. With regard to the sign and symptoms evaluated,
the following clinical pictures were considered: otitis,
pharyngo-tonsillitis, tonsillitis, sinusitis, rhino-pharyngitis,
bronchitis and pneumonia. During visit 1 and 5, the pa-
tients were asked to fill in a Visual Analogue Scale (VAS),
ranging from 0 (the worst) to 10 (the best situation). At
the end of the follow up, the investigators were also asked
to declare an estimate of the drug efficacy (in a scale from
0 to 5) and the drug tolerability (in a scale from 0 to 4).
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of the study drug. The compliance to the protocol was
evaluated at the end of the study, by comparing the num-
ber of tables still remaining in the blister and the number
of tablets that the patient recorded as assumed.
Concomitant drugs
The following drugs (immune-stimulants, anti-neoplastic,
cytokines, interferons, long term treatment with systemic
steroids) were not allowed during the study. Every other
treatment was permitted and the patient was asked to rec-
ord every assumption.
Definition of acute infectious episodes
Acute episodes of the upper respiratory airways were iden-
tified by the continuous presence of rhinorrhoea (both
sero-mucous and purulent), pharyngitis, and cough, lasting
at least 48 hours, with or without fever. Acute episodes of
the lower respiratory airways were defined as the con-
tinuous presence of at least one of the following signs or
symptoms: stridor, wheeze, crackles and rhonchi indraw-
ing, respiratory frequency >50 cycles/minute, cyanosis,
lasting at least 48 hours, with or without fever. Acute ep-
isodes of otitis were defined as the continuous presence
of pain, erythema and reduced or loss of tympanic mem-
brane mobility. Finally, an acute infectious episode was
defined as new if at least 72 hours had passed, in the
complete absence of symptoms, from the resolution of the
previous episode.
Patients’ consent withdrawal
Patients were allowed to withdraw from the treatment for
any reason. According to the protocol, when possible, the
adverse reactions and the use of drugs were recorded in re-
tired patients and the personal diary was retired. Any rele-
vant information was recorded in the CRF.
Patients’ compliance control
The Investigators instructed the patient to bring the boxes
of the drug to each visit. Treatment compliance was calcu-
lated at each study visit by the Investigator, by making a
cross-check on the vials and using the formula:
Compliance %ð Þ ¼ Tablets taken
Tablets which should have been taken
 100
The patient was considered as adhering to the thera-
peutic protocol if he/she had taken at least 80% of the
specified quantity of medicine. Treatment compliance was
recorded in the CRF by the Investigator.
Safety assessment
Patients on their patient’s diary and investigators in CRF
carefully monitored the occurrence of adverse reactions
(AR). These were classified as certain, likely, possible,unlikely, unrelated and not evaluable, according to the
definition of the protocol. ARs were also classified as
slight (if not interfering with daily activities), intermediate
(if interfering with the day activities) and severe (if the AR
inhibits daily activities).
Exclusion of the patient from the study
Patients were excluded from the study because of ad-
verse reaction(s) that, to the investigator’ judgment, were
incompatible with the study continuation or if the inves-
tigator had the intention to treat the patient with drugs
non allowed by the present protocol.
Patient’s diary
Patients were requested to fill in a diary containing per-
sonal information. In particular, in the presence of an
infectious episode (IE), a specific diary section was filled
in by the patient, indicating a) the beginning and the
end of the IE; b) the signs and symptoms (fever, dys-
pnoea, pain, cough and general status) on a 4 point scale
(0 = absent, 1 =mild, 2 =moderate; 3 = severe); c) treat-
ments administered (antibiotics, local or systemic cortico-
steroids, cough mixtures, mucolytics expectorants, NSAID
etc.); d) specialist visits; e) absence from work or school;
f) period of hospitalization and g) adverse events.
Statistical analysis
Statistical analysis was performed on the following three
populations: a) Intention-to-Treat (ITT) Population, de-
fined as all randomized patients who received at least one
dose of study medication and had at least one evaluation
of the primary parameter (assessment of efficacy by the
patient’s diary) after randomization. b) Per-Protocol (PP)
Population, defined as the set of ITT patients who com-
pleted the study without presenting any major violation of
the protocol. Major deviations from the protocol were de-
fined in the statistical analysis plan (SAP), approved prior
to the opening of the randomization code (breaking the
blind). c) Safety or Safety Set (SS) Population, defined as
all randomized patients who received at least one dose of
study drug. For the evaluation of the efficacy, Intention-
to-Treat (ITT) Population was considered as the primary
population for analysis. Demographic characteristics and
medical history of the patients were summarized for the
two study treatments using descriptive statistics (mean,
SD, median, for continuous variables and frequency tables
for categorical variables). The comparability of treatment
groups was assessed by applying appropriate statistical
tests, Student's t-test or Wilcoxon Rank-Sum Test for con-
tinuous variables, and Chi-Square test for dichotomous
variables. The primary variable was the total length, in
days, of infections of the respiratory tract observed in the
period between randomization and the end of study
visit (visit 5, month 6). The results obtained in the two
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(mean, SD and median) and compared using the ANCOVA
model. The analysis was performed with SAS by using the
MIXED Procedure. The statistical analysis and the relevant
date listings were produced using the SAS package. The
level of statistical significance was fixed at 5% (α = 0.05). All
statistical tests were two-tailed. All secondary efficacy vari-
ables were evaluated by using mean, SD and median for
continuous variables or frequency tables for categorical var-
iables. The comparison between the two treatment groups
was made through the application of the Student’s t-test or
in the same non-parametric Wilcoxon Rank Sum Test if
the parameter did not follow a distribution similar to the
normal. The analysis was assessed by applying the Kaplan-
Meier method and the comparison between the two groups
was evaluated using the log-rank test.
Results
Study population
A total of 188 patients (89 females and 79 males) were
eligible for the study. Out of these, 90 (49 females and
41 males) were included in the active group and 88 (50
females and 38 males) in the placebo group. One hun-
dred and seventy patients completed the study, 84 in the
active group and 86 in the placebo one. Thus, 18 pa-
tients (corresponding to less than 20% of the recruited
population) completed the study. Out of these, 10 were in
the treated group (5 were lost for adverse events, 3 for con-
sensus withdrawal and 2 for protocol violation). The
remaining seven patients from the placebo group, were lost
for adverse events (two patients), consensus withdrawal
(four patients) and the last one was lost during the follow
up. Data on FAS were obtained in 178 patients, and data
on safety in 181 patients. Smoking habits (84.8% were non
smokers and 15.2% smokers) were comparable in the two
groups. Similar results were observed for passive smoking
(14.6% complained passive smoking). The number of previ-
ous infections is shown in Table 1. Of note, there were no
differences in relation to gender behaviour.
Treatment compliance
Patients were particularly compliant to the treatment. In
fact, the compliance of the whole group was 99.98%,Table 1 Number of infections in the year preceding the
study
Placebo Treated
2 10 (11.4) 11 (12.2)
3 28 (31.8) 22 (24.4)
4 24 (27.3) 20 (22.2)
5 12 (13.6) 18 (20.0)
6 14 (15.9) 19 (21.1)being that of the active group 100% and that of the pla-
cebo group 99.96.
Primary objective
The primary objective of the study was the demonstra-
tion of reduction of the days in which patients suffered
from infectious episodes. In the whole period (i.e., from
the beginning of the treatment to the end of the follow
up, at the end of month 6), the mean number of days
with disease in the placebo group was 7.47 (SD 10.61)
and in the treated group 6.57 (SD 8.03). ANCOVA
analysis on the effect of the treatment resulted F = 4.70,
p = 0.032, (significant). The marginal means (i.e. the
means that could be expected if the parameters, such as
number of previous infections and total number of IE,
were balanced), were 7.883 days for the placebo group
and 6.159 days for the active group. The length of single
infectious episodes (in days) was largely superimposable
in the two groups (Wilcoxon p = 0.856). However, it
should be noted that 42% of placebo patients and 38% of
treated patients had 0 days with infectious disease dur-
ing the study period. During the follow up period, after
the end of the treatment, the number of days with infec-
tions was 1.19 in the placebo and 0.48 in the active
group (ANOVA p = 0.303, NS). For all these results, no
gender differences were observed.
Secondary endpoints
In details: a) the difference in the total number of infec-
tious episodes was not significant (0.99 and 1.12 for
placebo and bacterial lysate, respectively, ANCOVA
F = 0.181, p = 0.671, NS). Similar results were obtained
when the evaluation was performed at the end of the
treatment period (0.86 and 1.04 for placebo and bacterial
lysate, ANCOVA F = 0.574, p = 0.450, NS); b) the efficacy
on different signs and symptoms related to IE, such as
cough, dyspnoea, pain and fever was monitored by using
the patients’ diaries and CRF. No significant differences
were observed comparing the active group with the pla-
cebo one for all these parameters (Table 2). The large dif-
ference between the frequency of symptoms in the first
four months and the frequency in the last two is partially
explained by the fact that the beginning of the study was
in late autumn/beginning of winter, when the infections
are more frequent than during spring; c) the disease-free
period, evaluated as the time of occurrence of the first
IE after the end of the treatment cycles, was longer
(mean = 57.8 days) in the active group than in the placebo
one (mean = 45.8 days), even if not statistically significant
(log rank test p = 0.239); e) the use of antibiotics, anti-
inflammatory drugs, the association of both and the use of
bronchodilators were also evaluated (Table 3). No differ-
ences were observed in the use of concomitant therapies,
even if the risk of assuming antibiotics was 17% higher
Table 2 Signs and symptoms evaluated during the
clinical trial









Cough intensity Weak 29 (49.2) 42 (57.5) 4 (50.0) 2 (40.0)
Moderate 26 (44.1) 30 (41.1) 2 (25.0) 2 (40.0)
Severe 4 (6.8) 1 (1.4) 2 (25.0) 1 (20.0)
Total 59 73 8 5
Dyspnoea Weak 9 (52.9) 19 (70.4) 1 (33.3) 1 (33.3)
Moderate 6 (35.3) 8 (29.6) 0 (0.0) 1 (33.3)
Severe 2 (11.8) 0 (0.0) 2 (66.7) 1 (33.3)
Total 17 27 3 3
Pain Weak 16 (69.6) 26 (63.4) 4 (80.0) 4 (80.0)
Moderate 7 (30.4) 15 (36.6) 0 (0.0) 1 (20.0)
Severe 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0)
Total 23 41 5 5
Fever Weak 8 (30.8) 11 (32.4) 1 (25.0) 1 (50.0)
Moderate 17 (65.4) 23 (67.6) 2 (50.0) 1 (50.0)
Severe 1 (3.8) 0 (0.0) 1 (25.0) 0 (0.0)
Total 26 34 4 2
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suming anti-inflammatory drugs was also 8% (95% CI:
0.503 - 1.681) higher, while the risk of assuming broncho-
dilators was 11.8% (95% CI 0.367 - 2.119) lower in the
treated group. However, none of these statistics were sig-
nificant; f ) the days of work/school lost during the treat-
ment and follow up periods were 1.35 in the placebo
group and 1.30 in the active one, ANOVA p = 0.917, NS;
g) the well-being, evaluated by the patients using a five
point scale showed that no differences were evident, after
4 treatment cycles, between the treated group and the
placebo one (7.229 and 7.464 units, respectively, ANOVA
p = 0.321, NS). Similar results were observed after 6 treat-




Antibiotics No Count 57 (64.8%) 55 (61.1)
Yes Count 31 (35.2) 35 (38.9)
Anti-inflammatory drugs No Count 53 (60.2) 56 (62.2) 0.785
Yes Count 35 (39.8) 34 (37.8) (N.S.)
Antibiotics and anti-
inflammatory drugs
No Count 68 (77.3) 67 (74.4) 0. 659
Yes Count 20 (22.7) 23 (25.6) (N.S.)
Bronchodilators No Count 76 (86.4) 79 (87.8) 0. 659
Yes Count 12 (13.6) 11 (12.2) (N.S.)using a 6 point scale, showed that only one (1.2%) pla-
cebo patient had markedly deteriorated. No differences
were observed in 11.9% active and 8.1% placebo pa-
tients. An improvement was observed in 56% and 61%,
respectively and a marked improvement was observed
in 32.1% and 29.1%, respectively. However, these results
were not statistically significant (p = 0.584, NS); the tol-
erability, evaluated by the investigators was excellent in
52.4% and 54.7% of active and placebo patients, good
in 46.4% and 43.0%, and moderate in 1.2% and 2.3%,
respectively. P was 0.794, NS; finally, k). twenty adverse
reactions (related to 18 different patients) were re-
corded for the active group and 15 (12 patients) for the
placebo group. Out of these, one was possibly and two
were probably related to the treatment in the active
group. In the placebo group, only three were possibly re-
lated to the treatment. The treatment suspension was de-
cided by the investigators in four cases, even if in a single
patient the relationship with the treatment was consid-
ered probable. In two patients treated with the placebo,
the study was interrupted and the therapy was sus-
pended, even if any relationship with the administered
study was detected.
Discussion
The administration of bacterial lysates has been sug-
gested in the past for the prophylaxis of infections of
both high and low respiratory tracts [3,16-19]. Since the
beginning of this century, a number of clinical and la-
boratory evidences has been collected to explain the
mechanism of action of bacterial lysate and the relevant
clinical efficacy of this approach. Briefly, the administra-
tion of a bacterial lysate has been shown to induce the
maturation of dendritic cells [10,11], to enlarge the sub-
sets of specific T and B lymphocytes [12-14] as well as to
recruit cells of the innate immunity [8-11]. All these
involvments of the innate and adaptive immunity pro-
duce the secretion of specific antibodies directed to bac-
terial wall proteins, favouring the opsonisation of living
microbes and the subsequent killing mediated by macro-
phages and granulocytes [7,8]. For these reasons, the im-
mune system of treated patients seems to be alerted
against potential pathogens, resulting in an active prophy-
laxis of respiratory tract infections.
The composition, the administered dose, the treatment
schedule and the route of administration of different
bacterial lysates available in human therapy are hetero-
geneous. Indeed, a bacterial lysate can be constituted by
soluble proteins alone, by entire bacterial bodies, by
fragmented bacterial bodies and by a mixture of soluble
proteins and particulate antigens. The bacterial antigens
are administered in mouth, by allowing the adsorption
of bacterial fragments or proteins via the oral mucosa,
or administered in gastro-protected tablets, capsules or
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absorbed by the gut mucosa. Also the dose and the
treatment schedule are heterogeneous, ranging from mg
of bacterial bodies to micrograms of proteins, from 10-
day cycles to 45 days treatment etc. The bacterial lysate
of this study, (Buccalin ®), is constituted by four different
bacterial strains (Streptococcus pneumoniae, Streptococ-
cus haemolyticus, Staphylococcus aureus and Haemophi-
lus influenzae) and the total number of bacterial bodies
administered in a single tablet is 4.5 × 109. The total
dose administered in a cycle is 7 × 4.5 × 109 that is
31.5 × 109 and the total dose administered in the study
is 126 × 109. If we compare with other treatments, such
as PMBL, the administered dose is 48 × 109 in a day,
480 × 109 in the first ten days of the first month and
1440 × 109 in the first three-month cycle and 2880 × 109
in the two cycles provided. This comparison is harder with
other bacterial lysates, such as those containing a soluble
fraction of the bacterial antigen.
Despite the great difference between the administered
doses, the differences in the clinical outcome are small.
Indeed, a significant reduction of the number of days with
respiratory tract infections, including otitis, pharyngo-
tonsillitis, laryngitis and lung airway diseases, was ob-
served. This reduction was not associated to a reduction
of the number of episodes and also was not clearly associ-
ated to a reduction of the use of concomitant therapies,
such as antibiotics and anti-inflammatory drugs. On the
contrary, even if not significant, in patients with severe
symptoms, related to cough, fever, pain and dyspnoea, a
constant reduction of the number of episodes was ob-
served for patients of the active group.
All together, these results indicate that the treatment
with bacterial lysate (Buccalin ®) was well tolerated, be-
cause the number and the severity of adverse reactions
was very low, and) a clinical efficacy on the number of
days with infectious episodes of the respiratory tract was
observed. In addition, patients with more severe symp-
toms have a trend of more beneficial effects by the treat-
ment. These results have not only a personal impact on
patients' health status, but also on the community in
which patients are living. Indeed, the reduction of the
days with infections not only may be associated to a re-
duced possibility of the patient to infect relatives, friends
and colleagues, but also the economical cost for the
community is reduced. Actually, on this topic, the re-
sults of this study appear only marginal. Indeed, no clear
evidences have been observed on the use of concomitant
therapies and on days of absence from school or work.
Nevertheless, the number of days with infections was
7.47 in the placebo group and 6.57 in the treated group.
The marginal means were even more significant (7.88
and 6.33 for the placebo and the active group), a clear
indication that an almost 25% reduction of the numberof days with infections, a very good results in this kind
of studies, was achieved. This result is in line with those
obtained in other clinical studies performed on patients
with recurrent respiratory infections in the past, and
summarized in review studies [3] and accurate meta-
analyses [4].
In this context, strengths of the study are that the ob-
served positive result was achieved in patients that were
free to be treated with the best conventional therapeutic
armamentarium and that the random design equally dis-
tributed the severity of the diseases, the localization of
the infections and the concomitant used therapies.
On the contrary, weaknesses of this study are repre-
sented by certain heterogeneities of the study popula-
tion, which included patients with recurrent upper and
lower respiratory tract infection, at different degrees of
severity and the absence of a specific laboratory support
to the follow up.
Other considerations might be kept in mind in order
to better understand these results. Actually, the drug
was developed many years ago and the dose, the treat-
ment schedule and the composition were based on clin-
ical, experimental and therapeutic data available 20 years
ago. Indeed, the concomitant therapies available now-
adays are much more effective than those available in
the past. To these considerations, it should be added
that the number and the severity of respiratory infec-
tions are strictly related to the seasonality of the epi-
demics, the local weather and the characteristics of the
winter in which the study was carried out. Even more
interestingly, the local climate could strongly impact on
the patient's health. All these confounding elements
could not be controlled in such a study. For example, all
the patients that were eligible, had a number of infec-
tions >2 in the previous winter.Conclusions
As a matter of fact, about 50% of the same group of pa-
tients had no infections during the study. In these condi-
tions, the fact that a significant reduction of the number
of days with IE in the treated group was observed, fur-
ther supports the concept that the treatment with this
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